Last reviewed · How we verify
NCT04122937: CarFlog
Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer.
trial testing Cytoreductive surgery in Peritoneal Carcinomatosis in 30 participants. Completed in 30 March 2019.
1 June 2018
Quick facts
| Lead sponsor | University of Pisa |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 March 2017 |
| Primary completion | 1 June 2018 |
| Estimated completion | 30 March 2019 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Cytoreductive surgery
Conditions studied
- Peritoneal Carcinomatosis — all drugs for Peritoneal Carcinomatosis →
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Colon Cancer — all drugs for Colon Cancer →
Sponsor
University of Pisa
Who can join
Adults 25 to 75, female only, with Peritoneal Carcinomatosis or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Inflammation plays an important role in the pathogenesis of peritoneal carcinosis. Patients with elevated levels of different inflammation cytokines show a worse prognosis at the time of diagnosis. In women, ovarian and colon cancer are the main causes of peritoneal carcinosis and a comparison of these two different types of peritoneal invasion have not been conducted yet. We found interesting studying the role of immune response, in particular tumour-associated antigens (TAA) that modulate the metastatic process. We will investigate also mitochondrial defects, such as mutations in mt-DNA, potentially involved in carcinogenesis.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer.
Novak I, Yu H, Magni L, Deshar G. · · 2020 · cited 16× · PMID 33233631 · DOI 10.3390/ijms21228781 -
The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers.
Matsuoka T, Yashiro M. · · 2023 · cited 14× · PMID 37892233 · DOI 10.3390/biom13101551 -
Ligand-Gated Ion Channels: Prognostic and Therapeutic Implications for Gliomas.
Hey G, Rao R, Carter A, Reddy A, et al · · 2023 · cited 9× · PMID 37241023 · DOI 10.3390/jpm13050853
Verify or expand the search:
- PubMed search for NCT04122937
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cytoreductive surgery
Trials testing the same drug.
- NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
- NCT07177105 — Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC · Phase 2 · not yet recruiting
- NCT05375825 — Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive S · Phase 1 · withdrawn
- NCT06223763 — SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery · unknown
- NCT06292286 — Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer · NA · recruiting
Other recruiting trials for Peritoneal Carcinomatosis
Currently open trials in the same condition.
- NCT04107077 — Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advance · Phase 2 · recruiting
- NCT07001748 — Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G · Phase 2, PHASE3 · recruiting
- NCT06929013 — Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer. · NA · recruiting
- NCT07514494 — Intensification Treatment of Ovarian Cancer by PIPAC · Phase 2 · recruiting
- NCT07493876 — Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With · NA · recruiting
Other University of Pisa trials
Trials by the same sponsor.
- NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
- NCT07444229 — Team-Based Learning Integrated Into Clinical Simulation in Nursing Students · NA · not yet recruiting
- NCT07041983 — 24-h Energy Expenditure and Anti-obesity Medication · enrolling by invitation
- NCT07510685 — Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial) · NA · completed
- NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04122937 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pisa
- Last refreshed: 25 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04122937.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing